Targeting those biomarkers (inhibiting those biomarkers) may therefore be the potential therapeutic approach to delay the progression of LN, particularly interfering the four biomarkers (Beclin-1, LC3, ULK1, and ATG7) in the type IV LN. This evidence concerns the gene MAP1LC3A and lobular neoplasia.